Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Higher GCA was associated with lower dementia risk (hazard ratio = 0.865, 95% confidence interval = 0.756 to 0.990).
Why it matters
This study found that higher general cognitive ability was linked to lower dementia risk, and that education and occupational complexity did not add significantly once that was accounted for. The authors suggest that efforts to boost cognitive development in childhood may be more useful for reducing dementia risk than later-life cognitive training.
-
Current annual replacement cost of unpaid family care is between $96 and $182 billion, 44% of which is accounted for by dementia caregiving.
Why it matters
This modelling study estimated the current annual replacement cost of unpaid family care at between $96 and $182 billion, 44% of which is accounted for by dementia caregiving, projected to rise to $277-571 billion by 2060 with 53% for dementia caregiving. It also projected that opportunity costs of forgone earnings and productivity loss will grow faster, so it concerns caregiving economics rather than treatment, cure, or prevention.
-
A total of 120 people with delirium participated [median age 86.3, range 70-99, 67 (55.8%) female and 55 (45.8%) with dementia].
Why it matters
The 4AT test kept its accuracy for detecting delirium when repeated, and fewer patients than expected recovered within nine days. This is about assessing recovery from delirium, not treating or preventing Alzheimer's disease.
-
In 2021, global mortality from AD and other dementias among individuals aged 60 and older reached approximately 1,922,970.75 cases (95% CI: 480,348.08 to 5,104,315.95), and the prevalence was 52,560,253.51 cases (95% CI: 41,399,948.84 to 65,633,448.71).
Why it matters
In 2021, global mortality from Alzheimer's and other dementias among people aged 60 and older was about 1.9 million, with high BMI and high fasting plasma glucose as prominent risk factors, and cases projected to nearly quadruple by 2050. The paper calls for targeted interventions but does not test any treatment, cure, or prevention.
-
People living with dementia and their care partners benefit from services and supports from a wide variety of healthcare and social service professionals.
Why it matters
This article describes the dementia care workforce and identifies large gaps in tracking career pathways, assessing training impact, and understanding recruitment and retention. It calls for evaluation research but does not test any workforce intervention.
-
In mid-life, the sample sizes ranged from 4100 in 2022 to 5589 in 2017-18 and in late-life from 2799 in 2011-12 to 3762 in 2017-18.
Why it matters
This Australian analysis found the overall preventable proportion of dementia stayed stable over 15 years, but the mix of risk factors changed, with depression becoming the leading midlife modifiable risk factor and low-income groups facing substantially higher risk. It suggests targeted multidomain interventions could help reduce disparities, but does not test such interventions.
-
BackgroundLet's Talk Tech (LTT) is a self-administered web intervention for people with memory loss and their care partners that supports decision-making about digital health technologies.
Why it matters
In this study, most care partners wanted to share technology preference reports with family and clinicians, and 30 of 32 clinicians said they would want such reports. It concerns sharing preferences about digital health technologies, not treating or preventing Alzheimer's disease.
-
Our study suggested that the long‐term exposure to air pollution was associated an increased risk of the transitions from health to incident cataract, dementia or the progression of both conditions.
Why it matters
In 409,608 UK Biobank participants followed a median of 14.5 years, long-term exposure to air pollution, especially PM2.5, was associated with increased risk of developing cataract, dementia, and progression from cataract to both conditions. This supports air pollution as a modifiable risk factor but does not test any treatment or cure.
-
Of the 1388 studies identified, 70 met the inclusion criteria for this review.
Why it matters
This scoping review found that Lewy body dementia research in Latin America is underrepresented, with most studies being cross-sectional and only two clinical trials that lack rigorous methodology. It is about research gaps, not about treating, curing or preventing dementia.
-
Demonstrated utility of the mCRT warrants further investigation into comparisons between the A and B versions, free versus cued recall and changes in performance over time to better understand sensitivity for tracking memory decline over time based on age and AD clinical status.
Why it matters
This longitudinal study of a cued recall test found version differences and lower free and cued recall scores in people with mild cognitive impairment and Alzheimer's dementia, with one exception in the mild intellectual disability group. It concerns a memory test only and reports no treatment, cure, or prevention.
-
In this study, the total scores of caregiver burden, family resilience, and SOC were 45.64 ± 17.04, 175.30 ± 34.38, and 52.29 ± 15.91 among family caregivers of people with dementia.
Why it matters
This cross-sectional study found that caregiver burden was negatively correlated with family resilience and sense of coherence, and that family resilience significantly mediated the relationship between caregiver burden and sense of coherence. The authors recommend interventions to reduce caregiver burden and improve family resilience, but the study does not address treating, curing, or preventing Alzheimer's disease.
-
The reduction of hospital deaths is a policy priority in most developed countries.
Why it matters
This longitudinal study of English adults aged 50 and older found that dementia is a barrier to dying in a private home and is associated with a care home death. It suggests that community palliative care referral pathways cater to cancer diagnoses, and that private home-based services struggle to support adults with dementia to die at home.
-
= 0.01). We also found that greater use of emotion-focused coping and deriving greater gains in caregiving mitigated the negative association between caregiver financial difficulty and their distress and perception of PwSDs' well-being.
Why it matters
This cohort study found that greater use of emotion-focused coping and deriving greater gains in caregiving mitigated the negative association between caregiver financial difficulty and their distress and perception of the person's well-being. It suggests that financial support and coping-focused interventions may protect caregivers' wellbeing, but does not address treating, curing or preventing Alzheimer's disease.
-
BackgroundThere are 5.5 million people living with dementia in the United States (US), with the cost of unpaid care making up a significant portion of the care costs.
Why it matters
This modelling study estimated the annual cost of care attributable to dementia in 2019 at $53,502 per case in the United States, with the contribution of unpaid care to total costs ranging from 70.2% in the District of Columbia to 89.9% in Arizona. It found that higher costs of unpaid care were associated with lower medical spending on nursing facility care, so it is about the economic burden of care rather than treating, curing, or preventing Alzheimer's disease.
-
Nickel-based nanomaterials (NBNs) have seen a surge in usage across a variety of applications.
Why it matters
This review is about the health risks of nickel-based nanomaterials, not Alzheimer's disease. It describes toxic effects seen in laboratory and animal studies, including oxidative stress, inflammation and genotoxicity, and proposes safer designs, stricter regulation and new toxicity testing.
-
Apathy was significantly more prevalent in dementia and MCI patients compared to HC.
Why it matters
In this cross-sectional pilot study, apathy was more common in dementia and MCI patients than in healthy controls and was strongly associated with orbitofrontal sulci atrophy, with no significant correlation to depression, anxiety, or cognitive performance. The authors emphasize integrating apathy assessments into clinical practice and say larger, longitudinal studies are needed; this does not test any treatment.
-
At baseline, participants were aged 70-95 years (mean: 75.2 ± 4.3), with 54% being women.
Why it matters
In this study of adults aged 70 to 95 followed for a median of 8 years, incident loneliness in men and persistent loneliness in women were associated with higher dementia risk, while transient loneliness was not. Social isolation and poor social support were associated with cognitive decline but not with dementia risk, so the findings point to loneliness as a possible risk marker rather than a proven target for preventing or curing Alzheimer's disease.
-
Two clusters were identified in the microbiota at the phylum level that showed significant differences on a few microbiotas phylum.
Why it matters
This study found that greater gut microbiome dysbiosis was linked to worse cognitive function, and that this link was partly explained by greater brain age. The authors suggest targeting the gut microbiome as a possible way to ease age-related cognitive decline, but no intervention was tested.
-
COG-T CHD is the first clinical trial to evaluate the efficacy of computer-based cognitive training in patients with coronary heart disease, filling an important gap in the treatment evidence for cognitive digital therapy.
Why it matters
This paper describes the protocol for a randomized controlled trial testing computerized cognitive training in patients with coronary heart disease and cognitive impairment. No results are reported yet, so it cannot show whether the training is effective.
-
Participants in the study had an average age of 85.4 ± 7.1 years.
Why it matters
In this cross-sectional study of older patients with dementia with Lewy bodies, anemia was present in 46.9% and was associated with congestive heart failure, a higher number of medications, and depressive mood. The authors recommend clinicians recognize anemia's importance, but the study does not show that treating anemia changes dementia outcomes.
-
The analysis tools and statistical methods used in large neuroimaging research studies differ from those applied in clinical contexts, making it unclear whether these techniques can be translated to a memory clinic setting.
Why it matters
This work adapted the UK Biobank imaging framework for a memory clinic, producing thousands of imaging measures and replicating and finding associations with age, cognition, and dementia-related diagnoses. It is a methods and feasibility study about translating research imaging into clinical settings, not a test of treatment or prevention.
-
The Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet has been related to a lower risk of dementia and better cognitive function.
Why it matters
This study found that a blood marker reflecting adherence to the MIND diet was linked to better cognitive outcomes in people aged 55 and older. It is an observational study, so it cannot prove that the diet or the marker causes better cognition or prevents dementia.
-
Nutrition and exercise play a pivotal role in counteracting the effects of aging, promoting health, and improving physical fitness in older adults.
Why it matters
This perspective discusses how diet and exercise together may help preserve muscle mass, cognitive function, and quality of life in older adults, and notes that optimal dosages and timing remain unclear. It does not test any intervention for Alzheimer's disease, so it cannot show that these strategies prevent or treat dementia.
-
"Rapid-type" caregivers (n = 12) had a median age of 59 (range 45-73) years; 6 were female, and 9 were spouses.
Why it matters
This poetic analysis compared caregivers of rapidly progressive and slower-duration dementia and found that time enabled preparation for end-of-life care in the slower type. It concerns caregiving and end-of-life experiences, not treating or preventing Alzheimer's disease.
-
Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain.
Why it matters
This review discusses the evidence for lecanemab and donanemab, monoclonal antibody therapies that remove amyloid-beta from the brain and are intended for people with early Alzheimer's disease. It notes high-quality evidence of statistically significant group differences in trials, but also mixed views on the clinical relevance of these differences and the value for individual patients.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Cardiovascular Health Among Rural and Urban US Adults—Healthcare, Lifestyle, and Social Factors
- The Validity and Reliability of the Mini-Mental State Examination-2 for Detecting Vascular Mild Cognitive Impairment and Vascular Dementia in a Korean Population
- Cost-consequence analysis of the partner in balance program for informal carers of persons with dementia
- Explainable Machine Learning-Based Classification of Clinical Dementia Ratings Using a Tablet-Based Cognitive Assessment
- Neuropathology of cognitively normal elderly
- Type 2 Diabetes Mellitus, Cognitive Performance, and Incident Dementia; Identifying Mediating Pathways and Biomarkers From the Plasma Proteome
- Differential Effects by Mental Health Status of Filling the Medicare Part D Coverage Gap
- The pathobiology of vascular dementia
- Basal forebrain control of wakefulness and cortical rhythms
- The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study